Thus, SLZBS may mitigate hepatic steatosis by inhibiting the expressions of HTR2A in the liver and TPH-1 in the small intestine as well as by reducing the levels of 5-HT in the liver and small intestine. This evidence concerns the gene HTR2A and Hepatic steatosis.